ArticleAnnals of nuclear medicine2025
Suvmax of the lesion should be considered in the treatment plan for stage I non-small cell lung cancer.
Article in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Local Recurrence After Lung Segmentectomy-Risk Factors and Future Directions: A Contemporary Review.Cancers · 2026Review
- Prognostic Significance of Preoperative PET-CT SUVmax in Resected Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.Medicina (Kaunas, Lithuania) · 2026Article
- NHOC/NHOP as novel biomarkers for predicting lymph node metastasis in NSCLC using PET/CT radiomics and machine learning: a two-center retrospective study.European journal of nuclear medicine and molecular imaging · 2026Article
- Current real-life survival after segmentectomy for lung cancer.Frontiers in surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesHigh maximum standardized uptake value (SUVmax) is associated with poorly differentiated tumors and lymph node metastasis. It is still controversial which tumors can be treated with sublobar resection and there are publications stating that SUVmax of the tumor may be important in choosing sublobar resection. Our aim in this study is to examine the prognostic value of tumor SUVmax in stage 1 non-small cell lung cancer and to determine its place in sublobar resection preference.
methodsThe study included 314 patients who underwent wedge resection, segmentectomy or lobectomy for pathological stage I NSCLC with tumor size ≤ 3 cm between January 2008 and December 2020. SUVmax of the tumors are dichotomized according to ROC threshold value 5.2 and prognostic factors for recurrence-free and overall survival were analysed.
resultsIn the multivariate survival analysis, SUVmax (p = 0.012), lymphovascular and/or perineural invasion (p < 0.001) and visceral pleural invasion (p = 0.031) were found to be independent prognostic factors for recurrence-free survival; age (p = 0.027), sex (p = 0.010) and SUVmax (p = 0.036) for overall survival. While there was no difference between lobar or sublobar resection in terms of recurrence-free survival (p = 0.647) in patients with SUVmax ≤ 5.2, lobectomy was found to be advantageous over sublobar resection for recurrence-free survival in patients with SUVmax > 5.2 (76.6% ± 3.9% / 53.4% ± 12.1%, p = 0.006, respectively).
conclusionsHigh SUVmax (> 5.2) is associated with poor recurrence-free survival and overall survival rates in pathological stage 1 NSCLC patients. In stage 1 patients, sublobar resection should be avoided if the primary tumor has a high SUVmax.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.